Nutrition & Metabolic Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran; Nutrition Department, Faculty of Paramedicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Nutrition & Metabolic Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran; Nutrition Department, Faculty of Paramedicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Respir Med. 2018 Dec;145:28-34. doi: 10.1016/j.rmed.2018.10.016. Epub 2018 Oct 19.
BACKGROUND: Asthma is a heterogeneous disease, which usually associated with chronic airway inflammation. The anti-heat shock protein (anti-HSP) 70 is a novel risk factor for asthma. The aim of the present study was to survey the effect of saffron supplementation on anti-HSP70, high-sensitivity C-reactive protein (hs-CRP) and spirometry test in patients with allergic asthma. BASIC PROCEDURES: In this clinical trial, patients (N = 80, 32 women and 48 men, 18-65 years old) with mild and moderate allergic asthma were randomized into two groups: a group of patients who received two capsules of saffron (100 mg/d) and a control group who received two capsules of placebo for 8 weeks. Anti-HSP70, hs-CRP and spirometry test were determined in patients before (week 0) and after (week 8) intervention. SPSS software (version 16.0; Inc, Chicago, IL) was used for data analysis. MAIN FINDINGS: Saffron in comparison with placebo significantly reduced the hs-CRP (p < 0.001) and anti-HSP70 (p < 0.001) concentrations. In spirometry test, forced expiratory volume in first second(FEV1), forced vital capacity (FVC), FEV1/FVC ratio and forced expiratory flow 25-75%.(FEF 25-75) increased significantly in saffron in comparison to placebo group (p < 0.05). PRINCIPAL CONCLUSIONS: Results of the present study suggested that saffron supplementation in patients with allergic asthma decreased significantly anti-HSPs 70 and hs-CRP and also improved some spirometry test factors.
背景:哮喘是一种异质性疾病,通常与慢性气道炎症有关。抗热休克蛋白(anti-HSP)70 是哮喘的一个新的危险因素。本研究旨在调查藏红花补充剂对过敏性哮喘患者抗 HSP70、高敏 C 反应蛋白(hs-CRP)和肺功能检查的影响。
基本程序:在这项临床试验中,将 80 名(32 名女性和 48 名男性,年龄 18-65 岁)轻度和中度过敏性哮喘患者随机分为两组:一组患者服用两胶囊藏红花(100mg/d),另一组患者服用两胶囊安慰剂,持续 8 周。在干预前(第 0 周)和干预后(第 8 周)测定患者的抗 HSP70、hs-CRP 和肺功能检查。使用 SPSS 软件(版本 16.0;芝加哥,IL)进行数据分析。
主要发现:与安慰剂相比,藏红花显著降低了 hs-CRP(p<0.001)和抗 HSP70(p<0.001)的浓度。在肺功能检查中,第 1 秒用力呼气量(FEV1)、用力肺活量(FVC)、FEV1/FVC 比值和 25-75%用力呼气流量(FEF 25-75)在藏红花组显著增加,与安慰剂组相比(p<0.05)。
主要结论:本研究结果表明,藏红花补充剂可显著降低过敏性哮喘患者的抗 HSP70 和 hs-CRP,同时改善肺功能检查的一些指标。
J Complement Integr Med. 2014-2-6
Iran J Basic Med Sci. 2025
Antioxidants (Basel). 2024-9-4
Naunyn Schmiedebergs Arch Pharmacol. 2024-8
J Pharmacopuncture. 2022-9-30
Iran J Basic Med Sci. 2022-8
J Asthma Allergy. 2021-1-5